JP2014532636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532636A5 JP2014532636A5 JP2014537693A JP2014537693A JP2014532636A5 JP 2014532636 A5 JP2014532636 A5 JP 2014532636A5 JP 2014537693 A JP2014537693 A JP 2014537693A JP 2014537693 A JP2014537693 A JP 2014537693A JP 2014532636 A5 JP2014532636 A5 JP 2014532636A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- group
- medicament
- virus
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009385 viral infection Effects 0.000 claims 10
- 208000036142 Viral infection Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- VTAPXODOLMOLNK-PCYKNENESA-N [(2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-phenylmethanone Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(C(=O)C=2C=CC=CC=2)O[C@H](CO)[C@@H](O)[C@H]1O VTAPXODOLMOLNK-PCYKNENESA-N 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 229910003827 NRaRb Inorganic materials 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229940124522 antiretrovirals Drugs 0.000 claims 1
- 239000003903 antiretrovirus agent Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000004712 monophosphates Chemical class 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 CP(*)(NC(*)C(O*)=O)=O Chemical compound CP(*)(NC(*)C(O*)=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1159622 | 2011-10-24 | ||
| FR1159622A FR2981650B1 (fr) | 2011-10-24 | 2011-10-24 | Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement |
| PCT/FR2012/052433 WO2013060980A1 (fr) | 2011-10-24 | 2012-10-23 | Analogues de nucleosides pour le traitement d'une infection virale, et methode d'evaluation de la sensibilite audit traitement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014532636A JP2014532636A (ja) | 2014-12-08 |
| JP2014532636A5 true JP2014532636A5 (enExample) | 2015-12-03 |
Family
ID=47221470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537693A Pending JP2014532636A (ja) | 2011-10-24 | 2012-10-23 | ウイルス感染の処置のためのヌクレオシドアナログおよび該処置に対する感受性を評価するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9181294B2 (enExample) |
| EP (1) | EP2771344B1 (enExample) |
| JP (1) | JP2014532636A (enExample) |
| CA (1) | CA2849969A1 (enExample) |
| FR (1) | FR2981650B1 (enExample) |
| WO (1) | WO2013060980A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3203995A4 (en) * | 2014-10-09 | 2019-05-15 | Board of Regents of the University of Nebraska | COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS |
| EP3737359A4 (en) | 2018-01-12 | 2021-11-03 | Board of Regents of the University of Nebraska | ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM |
| CA3132832A1 (en) | 2018-04-09 | 2019-10-17 | Howard E. Gendelman | Antiviral prodrugs and formulations thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4924624A (en) * | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
| GB8921469D0 (en) * | 1989-09-22 | 1989-11-08 | Erba Carlo Spa | 5'-alkylphosphonylnucleosides as antivirals |
| OA09370A (en) * | 1990-06-21 | 1992-09-15 | Patrick T Prendergast Irlande | Administering particular compounds against various parasites, mycoplasmas, other indications and other infections. |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| KR20070004792A (ko) * | 2004-03-05 | 2007-01-09 | 캠브리지 바이오테크놀로지 리미티드 | 아데노신 수용체 작용제 |
-
2011
- 2011-10-24 FR FR1159622A patent/FR2981650B1/fr not_active Expired - Fee Related
-
2012
- 2012-10-23 EP EP12790609.7A patent/EP2771344B1/fr not_active Not-in-force
- 2012-10-23 JP JP2014537693A patent/JP2014532636A/ja active Pending
- 2012-10-23 WO PCT/FR2012/052433 patent/WO2013060980A1/fr not_active Ceased
- 2012-10-23 US US14/354,044 patent/US9181294B2/en not_active Expired - Fee Related
- 2012-10-23 CA CA2849969A patent/CA2849969A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7508501B2 (ja) | ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用 | |
| JP7371931B2 (ja) | 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| JP7673118B2 (ja) | 化合物、組成物、及び疾患の治療方法 | |
| CA2972014A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| JP6220484B1 (ja) | フィロウイルス科ウイルス感染症を処置するための方法 | |
| JP2013056886A5 (enExample) | ||
| JP2016529324A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2016515128A5 (enExample) | ||
| WO2014124430A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| ME02400B (me) | Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
| RU2015109132A (ru) | Пролекарственная форма тенофовира и ее фармацевтические применения | |
| JP2014510774A5 (enExample) | ||
| JP2017531038A5 (enExample) | ||
| JP2019526596A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2019510027A5 (enExample) | ||
| RU2010100821A (ru) | Производные азапептидов | |
| WO2017106710A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| JP2011246469A5 (enExample) | ||
| JP2016513113A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2022106920A (ja) | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 | |
| JP2024517807A (ja) | ヌクレオチド及びヌクレオシド治療組成物、組合せ、並びにそれらに関連する使用 | |
| JP2014532636A5 (enExample) |